Early vs standard zoledronic acid treatments for prostate cancer metastatic to bone
How to Cite
OrthoEvidence. Early vs standard zoledronic acid treatments for prostate cancer metastatic to bone. ACE Report. 2020;9(8):15. Available from: https://myorthoevidence.com/AceReport/Report/6335
Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)J Clin Oncol. 2014 Apr 10;32(11):1143-50. doi: 10.1200/JCO.2013.51.6500.
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Six hundred and forty-five patients with castration-resistant prostate cancer and bone metastases were randomized to either early administration of zoledronic acid or standard administration of zoledronic acid initiated following progression to castration-sensitive disease. The purpose was to determine whether early treatment would reduce time to developing a skeletal-related event (SREs) compared...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE